TOP STORY | STOCKS

Avience Biomedicals Ltd IPO: Dates, Price Details & Full Review

Avience Biomedicals Ltd IPO banner with healthcare products, IPO text and Acumen branding

The Avience Biomedicals Ltd IPO opens for subscription on June 18, 2026 and closes on June 22, 2026. It is an NSE SME book-built IPO from a healthcare diagnostics and medical devices company.

For SME IPOs, investors also need to consider valuation, liquidity, business sustainability, client concentration, and the higher minimum application amount.

This guide explains the Avience Biomedicals IPO in a simple, investor-friendly way. You will find the IPO dates, price band, lot size, GMP, company profile, financials, strengths, and risks.


Avience Biomedicals Ltd IPO: Key Details at a Glance

Here is everything that matters, in one table.

IPO Open DateJune 18, 2026
IPO Close DateJune 22, 2026 (cut-off 5 PM)
Issue TypeBook-built SME issue (100% fresh issue)
Price Band₹196 to ₹208 per share
Face Value₹10 per share
Lot Size1,200 shares
Minimum Investment (1 lot)≈ ₹2,49,600 at the upper band
Total Issue Size≈ ₹30.24 crore (14,53,800 fresh shares)
Listing PlatformNSE SME (Emerge)
RegistrarSkyline Financial Services Pvt Ltd
Lead ManagerFintellectual Corporate Advisors Pvt Ltd
Market MakerAsnani Stock Broker Pvt Ltd
Basis of allotmentJune 23, 2026
Refunds initiatedJune 24, 2026
Shares credited to dematJune 24, 2026
Listing on NSE SMEJune 25, 2026 (tentative)

About Avience Biomedicals 

Avience Biomedicals is an ISO-certified diagnostics and medical-device company that runs its manufacturing operations out of Noida, Uttar Pradesh. In plain terms, it makes the kits and machines that pathology labs and hospitals use to detect disease.

The product range is wide. It covers rapid test kits, molecular diagnostics, biochemistry analysers and reagents, haematology analysers, serology products and other medical devices, sold largely under its Avienbio brand. Its test kits target common infections like dengue, malaria, HIV, hepatitis and typhoid.

Customers sit on both sides of the market. Avience Biomedicals supplies pathology labs, microbiology labs, hospitals and research centres across India and a few overseas markets, working through B2B and B2G (business-to-government) channels. It also acts as a distributor and trader of medical equipment. As of January 31, 2026, it employed 75 permanent staff and 33 contractual workers.


Avience Biomedicals IPO GMP Today: 

As of June 17, 2026, IPO Watch reported the Avience Biomedicals IPO GMP at around ₹63, compared with ₹70 on June 16 and ₹40 on June 15. At the upper issue price of ₹208, this implies an indicative grey market premium of around 30%.

However, GMP should be treated carefully.

Grey Market Premium is an unofficial market indicator. It is not regulated by SEBI, NSE or BSE. GMP can change quickly before listing, and a high GMP does not guarantee listing gains. For SME IPOs, GMP-driven decisions can be risky because liquidity after listing may be limited.

A practical investor should use GMP only as a sentiment indicator. The real decision should depend on the company’s business model, valuation, financial performance, use of funds, risk factors and personal risk appetite.

For a beginner-friendly explanation, read Acumen’s guide: What is GMP in IPO?


Avience Biomedicals’ Financial Performance

On a consolidated basis, the growth story looks impressive. Revenue nearly doubled in FY25, and profit more than tripled.

Period (Consolidated)Revenue (₹ Cr)Net Profit (₹ Cr)
FY2424.372.14
FY2545.977.23
10M FY26 (to 31 Jan 2026)41.945.74

The return ratios are eye-catching too: an average return on net worth of about 44.7% and an average EPS near ₹14.9. At the ₹208 upper band, the issue is priced at roughly 15.8 times FY25 earnings, with a post-issue price-to-book of about 1.9 times.


Strengths of Avience Biomedicals IPO

1. Healthcare and diagnostics exposure

Avience Biomedicals operates in the healthcare diagnostics and medical devices segment. Diagnostics is an important part of India’s healthcare ecosystem because hospitals, pathology labs and research centres need reliable testing products.

2. Diversified product portfolio

The company is not dependent on only one product. Avience Biomedicals sells diagnostic kits, IVD products, analysers, reagents, serology products and related medical devices. This diversification can reduce product concentration risk, although category-wise revenue contribution should be checked in the RHP.

3. Strong recent revenue and profit growth

The company’s FY25 revenue and profit growth are attractive. Revenue almost doubled from FY24 to FY25, while profit increased more sharply.

4. Fresh issue structure

The issue is a fresh issue, so the money raised goes to the company. This can support business expansion if the funds are used efficiently.

5. Planned manufacturing expansion

A major part of the IPO proceeds is proposed for setting up a new manufacturing unit at YEIDA Medical Device Park in Uttar Pradesh.


Key Risks Investors Should Know

1. SME IPO risk

A SME IPO may be more volatile than a mainboard IPO. Post-listing liquidity may be limited, spreads can be wider, and price movements may be sharper.

2. High minimum application amount

The minimum investment is around ₹2.49 lakh at the upper price band. This is a large ticket size for many retail investors.

3. GMP can reverse quickly

The IPO GMP has already moved from ₹40 to ₹70, then to around ₹63 in a short period. This shows that grey market sentiment can change quickly.

4. Sustainability of growth

The company has delivered strong recent numbers, but investors should check whether the profit jump is sustainable. One strong year is encouraging, but long-term valuation depends on repeatable earnings.

5. Execution risk

The company plans to spend a large part of IPO proceeds on a new manufacturing unit. New capacity can support growth, but delays, cost overruns or lower-than-expected demand can affect returns.

6. Regulatory and quality risk

Diagnostics and medical devices are sensitive healthcare categories. Product quality, certifications, compliance and regulatory standards matter. Any quality issue may affect reputation, approvals and customer trust.


How to Apply for the Avience Biomedicals IPO

Investors can apply through ASBA net banking or through UPI using a broker platform. IPO Watch states that investors can apply via ASBA through bank accounts or through stock brokers using UPI.

Basic steps:

  1. Log in to your demat and trading account.
  2. Go to the IPO section.
  3. Select Avience Biomedicals Ltd IPO.
  4. Enter the bid quantity and price.
  5. For better allotment chances, many investors bid at the cut-off or upper price band.
  6. Approve the UPI mandate before the deadline.
  7. Check allotment status after finalisation.

New investors can visit Acumen Capital Market to explore demat and investment services. You may also read: IPO Allotment Process


Conclusion

The Avience Biomedicals Ltd IPO brings a growing diagnostics and medical devices company to the NSE SME platform. The company has reported strong revenue and profit growth, and the IPO proceeds are planned for manufacturing expansion, working capital and corporate purposes.

The IPO also has clear risks. The minimum application amount is high, the issue is on the SME platform, GMP is unofficial, and the sustainability of recent growth needs careful review. Investors should not treat grey market premium as a guaranteed listing signal.

For informed investors with SME IPO experience and a higher risk appetite, Avience Biomedicals may be worth studying in detail. For cautious or first-time investors, the safer route is to read the offer document, understand the risks and avoid applying only for listing gains.


Frequently Asked Questions

Q1. Is the Avience Biomedicals IPO worth applying for?

The company shows strong recent growth and high return ratios, but the issue looks fully priced, and the profit surge may not be repeatable. Read the RHP, weigh the steep minimum ticket, and match the decision to your own risk appetite.

Q2. How much money do I need to apply for the Avience Biomedicals IPO?

You need about ₹2,49,600 for one lot of 1,200 shares at the upper price band of ₹208. The amount stays blocked through UPI until allotment.

Q3. What will Avience Biomedicals do with the IPO money?

The IPO is a 100% fresh issue. Avience Biomedicals plans to use the funds for manufacturing expansion, working capital needs and general corporate purposes.

Q4. Should I apply for listing gains or long-term holding?

Apply only after checking the company’s fundamentals and risks. GMP may suggest listing interest, but it is unofficial and can change before listing.

Q5. What are the biggest risks in this IPO?

Key risks include rich valuation, uncertain profit sustainability, customer and supplier concentration, China import exposure and SME IPO liquidity risk.

Q6. Is the Avience Biomedicals IPO fairly priced?

At the upper price band, the IPO appears fully priced. The company has strong recent growth, but investors should check whether that growth can continue.

Q7.What are my chances of allotment?

Allotment depends on subscription demand. If the IPO is oversubscribed, shares are allotted through a lottery, and refunds are expected from June 24, 2026.

Sl.NoBranchNamePhone NoEmailBranch Address
1MumbaiPravin Pandey 7511188614pravin.pandey@acumengroup.in Office No. 10, Ground Floor, Veena Beena Arcade. Guru Nanak Road, Bandra (West) , Mumbai – 400050
Sl.NoNamePhone NoEmailBranch Address Branch
1Digvijaysinh Jashvantsinh Solanki7593979113digvijay.s@acumengroup.in203,President Plaza,Thaltej Cross Road Circle, SG Road, Opp. Mukthidham Derasar, Thaltej, Ahmedabad-380054
Sl.NoNamePhone NoEmailBranch Address Branch
1Lijo Jose8428944466 / 8281436272lijo.jose@acumengroup.in1st Floor,No:51/68, South West Boag Road, Opposite SS Kalyan Mahal, Thiyagaraya Nagar, Chennai 600017 Tamil Nadu
2Hasheem Muhammed 8428933366hasheem.m@acumengroup.in 1st Floor,No:51/68, South West Boag Road, Opposite SS Kalyan Mahal, Thiyagaraya Nagar, Chennai 600017 Chennai
3Siva Prakasam T 9367570562 sivaprakasam.t@acumengroup.in No:57, Race Course Road, Near Income Tax Office,Near Income Tax Office,Coimbatore-641018 Coimbatore
4Ragothman Ranganathan 9778429172ragothman.r@acumengroup.in 9/11, 1st Floor,Opp Sudha Hospital,Perundurai Road,Erode-638001 Erode
5Vigneswaran Balasubramanian 9344203315 vigneswaran.s@acumengroup.in No: 82 Chandragandhi Nagar,Ponmeni,Bye Pass Road,Pretham Plaza,3rd Floor,Madurai 625016 Madurai
6Vinoth Kumar V 8089968222vinothkumar.v@acumengroup.in 3-1-97/7, IOB bank upstair,theni- kumily Road , palanichettipatti,Theni, Tamilnadu, Pin-625531 Theni
Sl.NoNamePhone NoEmailBranch Address Branch
1Suryanarayana Korra9346277007suryanarayana.k@acumengroup.inDr No: 47-10-10, 1st Floor, Rednam Regency, 2nd Lane, Dwaraka Naagar, Visakhapatnam: 530016, Andhra PradeshVisakhapatnam
2Chakka Lokesh Kumar 8714755506lokesh.k@acumengroup.in Vijayawada
3Tadi Surendra Baba8714755528surendrababa.t@acumengroup.in46-14-12, 2nd floor,Annapurna Arcade, Danavaipeta,Rajahmundry - 533103Rajahmundry
Sl.NoNamePhone NoEmailBranch Address Branch
1Krishna Bhat9645119004 / 8583854400krishna.bhat@acumengroup.in2nd floor. gl tower no 15/1 ,2nd main 7th cross above Apollo pharmacy ,near n r colony BMTC bus stand ,Bangalore 560019N R Colony
2Nagesh D M 9341103366nagesh.dm@acumengroup.in No. 9, 2nd Floor 2 nd Main ,8th Cross, 1st Stage, Indira Nagar,Near B.D.A Complex,Banglore-560038 Indira Nagar
3Krishna Bhat 9645119004 krishna.bhat@acumengroup.in 3nd Floor, Manasa Towers, M.G Road, Near Pvs Circle, Manglore-575003 Ph: 0824-3200141 Manglore
4Nirmala B6282014318nirmala.b@acumengroup.inRoom No. 8, 12th Cross, Ideal Homes Township, Rajarajeshwari Nagar, Bangalore-560098Rajarajeshwari Nagar
Sl.NoBranchNamePhone NoEmailBranch Address
1KaloorPadmaraj9745052755padmaraj.l@acumengroup.inNo:36/1296, A15, MES Building, Judges Avenue, Kaloor,Kochi 682017
2Thrissur Jancy Leo 8113885566jancy.leo@acumengroup.in Door No. 25/395/28,2nd Floor, Pathayappura Building,Round South, Thrissur - 680 001
3ThiruvallaNibin Raj9745044855nibin.raj@acumengroup.inBuilding No. 620. Ground Floor, Thiruvalla Municipality Ward No. 36, Illampallil Towers, MC road, Thiruvalla - 689101
4TrivandrumNibin Raj9745044855nibin.raj@acumengroup.in 2G,Tc 26/114(3),Capitol Center, Trivandrum-695001
5PalaKrishna Kumar B9567650448krishnakumar.b@acumengroup.in2nd Floor, Joseph Arcade, Pala P O,Kottayam-686575
6Calicut Midlaj P 9388239888midlaj.p@acumengroup.in3rd Floor,Parco Complex,Kallai Road,Calicut -673001
7Kasaragod/Waynad/Kannur Joji T Mathew 9745944406 joji.mathew@acumengroup.in2nd Floor, Fathima Arcade, Opp.New Bus Stand, Kasaragod – 671121
8Rest of Kerala Jinkle Joseph A J8714755524jinkle.j@acumengroup.in2nd Floor, S.T Reddiar & Sons Veekshanam Road, Kochi Pin: 682035